Atom Investors’s NextCure NXTC Stock Holding History

Atom Investors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,322	Closed	-$310K	–	300
2022 Q1	$310K	Buy	5,322 +1,727	+48%	+$108K	0.15%	134
2021 Q4	$259K	Buy	+3,595	New	+$301K	0.04%	219

Other funds holding NXTC

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Atom Investors's NXTC Position: Q2 2022 in Review

Atom Investors sold out of NextCure (NXTC) in Q2 2022, closing a stake of 5,322 shares — an estimated $310K sold.

Atom Investors first reported a position in NXTC in Q4 2021 and held it in 2 quarters. The position peaked at $310K in Q1 2022. 51 funds tracked by Wall St. Rank hold NXTC as of Q2 2022.

Atom Investors reported no remaining NextCure position as of Q2 2022 after selling out during the quarter.
Atom Investors sold 5,322 NextCure shares in Q2 2022, an estimated $310K.
Atom Investors first reported a position in NextCure in Q4 2021 and held it in 2 quarters.
Atom Investors's NextCure position peaked at $310K in Q1 2022.
51 funds tracked by Wall St. Rank held NextCure as of Q2 2022.

Based on Atom Investors's 13F filing for Q2 2022, filed 15 Aug 2022.